Novavax critic Shah Capital ends its activism campaign
Shah Capital has ended attempts to exert influence over vaccine firm Novavax, bringing more than years of pressure on management to an end.
Novavax
NASDAQ: NVAX $9.70 USD
Novavax is a vaccine company built on a recombinant protein-based nanoparticle platform and its saponin-based Matrix-M adjuvant, used in Nuvaxovid (NVX-CoV2373), its protein-based COVID-19 vaccine. The company develops adjuvanted vaccines for infectious diseases and partners with public-health bodies and manufacturers on supply and technology transfer.
Company Info
Sector:Vaccines / Biotechnology
Headquarters:Gaithersburg, Maryland, USA
Founded:1987
Website:www.novavax.com/
Clinical Development Pipeline
Nuvaxovid (NVX-CoV2373)
Target: Recombinant SARS-CoV-2 spike protein nanoparticle with Matrix-M adjuvantCOVID-19-Influenza Combination (CIC)
Target: Combination nanoparticle vaccine with Matrix-M adjuvantMatrix-M
Target: Saponin-based adjuvantRecent News
Leadership Team
John C. Jacobs
President and Chief Executive Officer